|
Richard Murray, Ph.D. has served as PDL BioPharma’s Vice President, Research since April 2003 and was recently made Senior Vice President, Chief Scientific and Technical Officer. Prior to PDL BioPharma, Dr. Murray co-founded Eos Biotechnology, Inc., where he served as Vice President, Research at Eos from February 1998 to April 2003 before joining PDL BioPharma’s management team through the company’s acquisition of Eos. Dr. Murray was responsible for the discovery and transition of antibody-based therapeutic candidates from research to development. Prior to Eos, Dr. Murray was a staff scientist, then senior staff scientist at DNAX Research Institute, where he established the transgenic and knock-out mouse program. Dr. Murray received a Ph.D. from the University of North Carolina in Chapel Hill with his work in the area of immuno-genetics.
| 